Compare MTB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTB | WAT |
|---|---|---|
| Founded | 1856 | 1958 |
| Country | United States | United States |
| Employees | 22278 | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6B | 29.3B |
| IPO Year | N/A | 1996 |
| Metric | MTB | WAT |
|---|---|---|
| Price | $218.23 | $347.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 17 |
| Target Price | $228.59 | ★ $379.19 |
| AVG Volume (30 Days) | 881.8K | ★ 889.0K |
| Earning Date | 04-15-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | N/A | ★ 10.76 |
| Revenue | N/A | ★ $3,165,286,000.00 |
| Revenue This Year | $9.87 | $104.66 |
| Revenue Next Year | $3.66 | $10.40 |
| P/E Ratio | ★ $13.63 | $31.78 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $174.76 | $275.05 |
| 52 Week High | $239.00 | $414.15 |
| Indicator | MTB | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 64.76 |
| Support Level | $212.98 | $340.09 |
| Resistance Level | $222.68 | $397.85 |
| Average True Range (ATR) | 4.08 | 11.94 |
| MACD | -0.41 | 2.55 |
| Stochastic Oscillator | 58.87 | 92.87 |
M&T Bank is a US regional bank with around $213 billion in assets as of Dec. 30, 2025. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust business.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.